Policy

In this video, Steve Marciniak, RPh, speaks of the challenges and value of specialty drugs.

Money Well Spent?

SABCS Conference Coverage

Interview With Allen S. Lichter, MD, Chief Executive Officer, American Society of Clinical Oncology

Cathleen Biga states that with a good amount of work and significant cost meaningful use can be achieved.

UPMC Oncologists: Pioneers in the Clinical Pathways Movement

Use of bioimpedance spectroscopy to aid in post“breast cancer assessments for lymphedema can be cost saving for healthcare organizations in the United States.

Panelists agree that congress does not want these cuts in physician payment rates and Medicare.

The panel members discuss the question of how much would it cost to abolish the SGR.

Michael Einodshofer, RPh, MBA, points out the benefits to members from Site of Care Optimization programs.

Dr. Butler answers why he is not confident that costs will ever be controlled.

Higher use of performance-based payment mechanisms and capitated arrangements is associated with a decrease in the amount of time physicians spend with patients with cancer.

Active expert peer-to-peer consultation with prescribing oncologists can promote adherence to guidelines and lead to cost reductions without risk of neutropenic fever, with or without hospitalization, for patients with cancer.

Stereotactic body radiation therapy for low- to intermediate-risk prostate cancer has potential cost savings and may improve access to radiation, increase convenience, and boost quality of life.

Payment reform may be used to better align appropriate financial incentives with better quality of care.